Last reviewed · How we verify
Epidiolex
At a glance
| Generic name | Epidiolex |
|---|---|
| Also known as | Cannabidiol; CBD, Cannabidiol, CBD, Cannabidiol Oral Solution, Epidyolex |
| Sponsor | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center |
| Target | N-arachidonyl glycine receptor, Cannabinoid receptor 2, Caspase-1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Lennox-Gastaut syndrome
- Severe myoclonic epilepsy in infancy
Common side effects
- Transaminase elevations
- Decreased appetite
- Diarrhea
- Somnolence
- Fatigue, malaise, and asthenia
- Rash
- Insomnia, sleep disorder, and poor quality sleep
- Infections
- Pyrexia
- Vomiting
- Weight decreased
- Gastroenteritis
Serious adverse events
- Transaminase elevation (discontinuation)
- Somnolence/sedation/lethargy (discontinuation)
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Sublingual Cannabidiol for Anxiety (PHASE2)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Consumer Perceptions of Cannabidiol (CBD) Health Claims (NA)
- Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder (PHASE2)
- MIVetsCan: Can-Coach Trial (Phase 2) (NA)
- CBD for Pain Following Orthopedic Shoulder Surgery (PHASE1, PHASE2)
- CBD for Breast Cancer Primary Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epidiolex CI brief — competitive landscape report
- Epidiolex updates RSS · CI watch RSS
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center portfolio CI